UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 3, 2011

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES x NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES x NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer x

Accelerated filer o

Non-accelerated filer o

Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES o NO x

At May 9, 2011, 7,901,130,426 shares of the issuer s voting common stock were outstanding.

FORM 10-Q

For the Quarter Ended

April 3, 2011

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three months ended April 3, 2011 and April 4, 2010

Condensed Consolidated Balance Sheets as of April 3, 2011 and December 31, 2010

Condensed Consolidated Statements of Cash Flows for the three months ended April 3, 2011 and April 4, 2010

Notes to Condensed Consolidated Financial Statements

Review Report of Independent Registered Public Accounting Firm

24

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

25

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

55

Item 4.

Controls and Procedures

55

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

56

Item 1A.

Risk Factors

59

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

59

Item 3.

Defaults Upon Senior Securities

59

Item 5.

Other Information

59

Item 6.

Exhibits

60

Signature

61

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

(millions, except per common share data)

April 3,

2011

April 4,

2010

Revenues

16,502

16,576

Costs and expenses:

Cost of sales(a)

3,693

4,202

Selling, informational and administrative expenses(a)

4,503

4,403

Research and development expenses(a)

2,091

2,221

Amortization of intangible assets

1,376

1,409

Acquisition-related in-process research and development charges

74

Restructuring charges and certain acquisition-related costs

894

706

Other deductions net

827

412

Income from continuing operations before provision for taxes on income

3,118

3,149

Provision for taxes on income

894

1,135

Income from continuing operations

2,224

2,014

Discontinued operations:

Income from operations net of tax

10

19

Gain on sale of discontinued operations net of tax

Discontinued operations net of tax

10

21

Net income before allocation to noncontrolling interests

2,234

2,035

Less: Net income attributable to noncontrolling interests

12

Net income attributable to Pfizer Inc.

2,222

2,026

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.28

0.25

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.28

0.25

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.28

0.25

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.28

0.25

Weighted-average shares used to calculate earnings per common share:

Basic

7,982

8,061

Diluted

8,035

8,101

Cash dividends paid per common share

0.20

0.18

(a)

Exclusive of amortization of intangible assets, except as disclosed in Note 11.B Goodwill and Other Intangible Assets: Other Intangible Assets.

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(millions of dollars)

April 3,

2011

Dec. 31,

2010

(Unaudited)

Assets

Cash and cash equivalents

730

1,735

Short-term investments

23,279

26,277

Accounts receivable, less allowance for doubtful accounts

15,182

14,426

Short-term loans

406

467

Inventories

8,467

8,275

Taxes and other current assets

8,755

8,394

Assets of discontinued operations and other assets held for sale

1,425

1,439

Total current assets

58,244

61,013

Long-term investments and loans

9,811

9,747

Property, plant and equipment, less accumulated depreciation

18,833

18,645

Goodwill

44,853

43,928

Identifiable intangible assets, less accumulated amortization

58,497

57,555

Taxes and other noncurrent assets

4,718

4,126

Total assets

194,956

195,014

Liabilities and Shareholders Equity

Short-term borrowings, including current portion of long-term debt

6,093

5,603

Accounts payable

3,750

3,994

Dividends payable

1,601

Income taxes payable

1,958

951

Accrued compensation and related items

1,849

2,080

Other current liabilities

15,338

14,256

Liabilities of discontinued operations

182

151

Total current liabilities

29,171

28,636

Long-term debt

35,308

38,410

Pension benefit obligations

5,929

6,194

Postretirement benefit obligations

3,041

3,035

Noncurrent deferred tax liabilities

19,414

18,628

Other taxes payable

6,590

6,245

Other noncurrent liabilities

4,970

5,601

Total liabilities

104,423

106,749

Preferred stock

49

52

Common stock

444

444

Additional paid-in capital

70,925

70,760

Employee benefit trusts

(6

(7

Treasury stock

(24,215

(22,712

Retained earnings

44,926

42,716

Accumulated other comprehensive loss

(2,056

(3,440

Total Pfizer Inc. shareholders equity

90,067

87,813

Equity attributable to noncontrolling interests

466

452

Total shareholders equity

90,533

88,265

Total liabilities and shareholders equity

194,956

195,014

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Three Months Ended

(millions of dollars)

April 3,

2011

April 4,

2010

Operating Activities:

Net income before allocation to noncontrolling interests

2,234

2,035

Adjustments to reconcile net income before allocation to noncontrolling interests to net

cash provided by/(used in) operating activities:

Depreciation and amortization

2,104

2,051

Share-based compensation expense

122

138

Asset write-offs and impairment charges

165

59

Acquisition-related in-process research and development charges

74

Deferred taxes from continuing operations

(120

840

Other non-cash adjustments

(2

260

Benefit plan contributions (in excess of)/less than expense

(383

163

Other changes in assets and liabilities, net of acquisitions and divestitures

522

(11,980

Net cash provided by/(used in) operating activities

4,642

(6,360

Investing Activities:

Purchases of property, plant and equipment

(250

(305

Purchases of short-term investments

(3,352

(2,178

Proceeds from redemptions and sales of short-term investments, net

8,406

11,388

Purchases of long-term investments

(1,932

(858

Proceeds from redemptions and sales of long-term investments

888

1,127

Acquisitions, net of cash acquired

(3,169

Other investing activities

134

220

Net cash provided by investing activities

725

9,394

Financing Activities:

Increase in short-term borrowings

2,682

1,892

Principal payments on short-term borrowings, net

(2,220

(3,663

Principal payments on long-term debt

(3,878

(9

Purchases of common stock

(1,430

Cash dividends paid

(1,591

(1,441

Other financing activities

33

10

Net cash used in financing activities

(6,404

(3,211

Effect of exchange-rate changes on cash and cash equivalents

32

(42

Net decrease in cash and cash equivalents

(1,005

(219

Cash and cash equivalents at beginning of period

1,735

1,978

Cash and cash equivalents at end of period

730

1,759

Supplemental Cash Flow Information:

Cash (refunded)/paid for income taxes

(134

10,547

Cash paid for interest

687

792

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation

We prepared the condensed consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three-month periods ended February 27, 2011, and February 28, 2010. We have made certain reclassification adjustments to conform prior-period amounts to the current presentation, primarily related to discontinued operations (see Note 4. Discontinued Operations) and segment reporting (see Note 15. Segment, Product and Geographic Area Information).

On January 31, 2011, we completed the tender offer for all of the outstanding shares of common stock of King Pharmaceuticals, Inc. (King) and acquired approximately 92.5% of the outstanding shares for approximately $3.3 billion in cash. On February 28, 2011, we acquired the remaining outstanding shares of King for approximately $300 million in cash (for additional information, see Note 3. Acquisition of King Pharmaceuticals, Inc.). Commencing from January 31, 2011, our financial statements include the assets, liabilities, operating results and cash flows of King. As a result, and in accordance with our domestic and international reporting periods, our condensed consolidated financial statements for the quarter ended April 3, 2011 reflect approximately two months of King s U.S. operations and approximately one month of King s international operations.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this document. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results.

The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2010.

Note 2. Adoption of New Accounting Policies

The provisions of the following new accounting standards were adopted as of January 1, 2011 and did not have a significant impact on our condensed consolidated financial statements:

New guidelines that address the recognition and presentation of the annual fee paid by pharmaceutical companies beginning on January 1, 2011 to the U.S. Treasury as a result of U.S. Healthcare Legislation. As a result of adopting this new standard, we are recording the annual fee ratably throughout the year in the Selling, informational and administrative expenses line item in our condensed consolidated statement of income.

An amendment to the guidelines that address the accounting for multiple-deliverable arrangements to enable companies to account for certain products or services separately rather than as a combined unit.

Note 3. Acquisition of King Pharmaceuticals, Inc.

On January 31, 2011 (the acquisition date), we completed our tender offer for all of the outstanding shares of common stock of King at a purchase price of $14.25 per share in cash and acquired approximately 92.5% of the outstanding shares. On February 28, 2011, we acquired all of the remaining shares of King for $14.25 per share in cash. As a result, the total fair value of consideration transferred for King was approximately $3.6 billion in cash ($3.2 billion, net of cash acquired).

King s principal businesses consist of a prescription pharmaceutical business focused on delivering new formulations of pain treatments designed to discourage common methods of misuse and abuse; the Meridian auto-injector business for emergency drug delivery, which develops and manufactures the EpiPen; an established products portfolio; and an animal health business that offers a variety of feed-additive products for a wide range of species.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following table summarizes the provisional recording, primarily at fair value, of the assets acquired and liabilities assumed as of the acquisition date:

(millions of dollars)

Amounts

Recognized as of

Acquisition Date

(Provisional)

Working capital, excluding inventories

210

Inventories

340

Property, plant and equipment

413

Identifiable intangible assets, excluding in-process research and development

1,781

In-process research and development

301

Net tax accounts

(384

All other long-term assets and liabilities, net

114

Total identifiable net assets

2,775

Goodwill

780

Net assets acquired/total consideration transferred

3,555

As of the acquisition date, the fair value of accounts receivable approximated the book value acquired. The gross contractual amount receivable was $200 million, virtually all of which is expected to be collected.

Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recorded as part of the acquisition of King includes the following:

the expected synergies and other benefits that we believe will result from combining the operations of King with the operations of Pfizer;

any intangible assets that do not qualify for separate recognition, as well as future, yet unidentified projects and products; and

the value of the going-concern element of King s existing businesses (the higher rate of return on the assembled collection of net assets versus if Pfizer had acquired all of the net assets separately).

Goodwill is not amortized and is not deductible for tax purposes. While the allocation of goodwill among reporting units is not complete, we expect that substantially all of the goodwill will be related to our biopharmaceutical reporting units (see Note 11. Goodwill and Other Intangible Assets for additional information).

The assets and liabilities arising from contingencies recognized at acquisition date, which are subject to change, are not significant to Pfizer s financial statements.

The recorded amounts are provisional and subject to change. Specifically, the following items are subject to change:

Amounts for intangibles, inventory and property, plant and equipment (PP&E), pending finalization of valuation efforts for acquired intangible assets as well as the completion of certain physical inventory counts and the confirmation of the physical existence and condition of certain PP&E assets.

Amounts for environmental contingencies, pending the finalization of our assessment and valuation of environmental matters.

Amounts for legal contingencies, pending the finalization of our examination and evaluation of the portfolio of filed cases.

Amounts for income tax assets, receivables and liabilities pending the filing of King s pre-acquisition tax returns and the receipt of information from taxing authorities, which may change certain estimates and assumptions used.

The allocation of goodwill among reporting units.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following table presents information for King that is included in Pfizer s condensed consolidated statement of income from the acquisition date, January 31, 2011, through Pfizer s first-quarter 2011 domestic and international quarter-ends:

(millions of dollars)

King s Operations

Included in Pfizer s First

Quarter 2011 Results

Revenues

224

Loss from continuing operations attributable to Pfizer Inc. common shareholders(a)

(69

(a)

Includes purchase accounting adjustments related to the fair value adjustments for acquisition-date inventory estimated to have been sold ($57 million pre-tax), amortization of identifiable intangible assets acquired from King ($29 million pre-tax) and restructuring and integration costs ($95 million pre-tax).

The following table presents supplemental pro forma information as if the acquisition of King had occurred on January 1, 2010:

Pro Forma Consolidated Results

Three Months Ended

(millions of dollars, except per share data)

April 3,

2011

April 4,

2010

Revenues

16,611

16,949

Income from continuing operations attributable to Pfizer Inc. common shareholders

2,313

1,910

Diluted earnings per share attributable to Pfizer Inc. common shareholders

0.29

0.24

The unaudited pro forma consolidated results do not purport to project the future results of operations of the combined company nor do they reflect the expected realization of any cost savings associated with the acquisition. The unaudited pro forma consolidated results reflect the historical financial information of Pfizer and King, adjusted for the following pro forma pre-tax amounts:

Elimination of King s historical intangible asset amortization expense ($6 million in 2011 and $41 million in 2010).

Additional amortization expense (approximately $14 million in 2011 and $43 million in 2010) related to the fair value of identifiable intangible assets acquired.

Additional depreciation expense (approximately $1 million in 2011 and $3 million in 2010) related to the fair value adjustment to property, plant and equipment acquired.

Adjustment related to the fair value adjustments to acquisition-date inventory estimated to have been sold (elimination of $57 million charge in 2011 and addition of $57 million charge in 2010).

Adjustment for acquisition-related costs directly attributable to the acquisition (elimination of $117 million of charges in 2011 and addition of $117 million of charges in 2010, reflecting charges incurred by both King and Pfizer).

Note 4. Discontinued Operations

We evaluate our businesses and product lines periodically for their strategic fit within our operations. In the first quarter of 2011, we decided to sell our Capsugel business. In connection with the decision to sell this business, for all periods presented, the operating results associated with this business have been reclassified into Discontinued operations net of tax in the Condensed Consolidated Statements of Income, and the assets and liabilities associated with this business have been adjusted to fair value, less costs to sell, and reclassified into Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in the Condensed Consolidated Balance Sheets.

On April 4, 2011, we announced that we had entered into an agreement to sell Capsugel to an affiliate of Kohlberg Kravis Roberts & Co. L.P. for $2.375 billion in cash. The sale is subject to customary closing conditions, including regulatory approval in certain jurisdictions, such as the U.S. and the European Union, among others. We expect the transaction to be completed in the third quarter of 2011, assuming receipt of the required regulatory clearances and the satisfaction of other closing conditions.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following amounts, substantially all of which relate to our Capsugel business, have been segregated from continuing operations and included in Discontinued operations net of tax in our Condensed Consolidated Statements of Income:

Three Months Ended

(millions of dollars)

April 3,

2011

April 4,

2010

Revenues

177

174

Pre-tax income from discontinued operations

28

30

Provision for taxes

(18

(11

Income from discontinued operations net of tax

10

19

Pre-tax gain on sale of discontinued operations

Provision for income taxes

(1

Discontinued operations net of tax

10

21

The following assets and liabilities, which include assets and liabilities held for sale related to our Capsugel business, and other assets held for sale, have been segregated and included in Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in our Condensed Consolidated Balance Sheets:

(millions of dollars)

April 3,

2011

Dec. 31,

2010

Accounts receivable

179

186

Inventories

144

130

Taxes and other current assets

39

47

Property, plant and equipment

993

1,009

Goodwill

19

19

Identifiable intangible assets

Taxes and other noncurrent assets

45

45

Assets of discontinued operations and other assets held for sale

1,425

1,439

Current liabilities

133

124

Other liabilities

49

27

Liabilities of discontinued operations

182

151

Net cash flows of our discontinued operations from each of the categories of operating, investing and financing activities were not significant.

Note 5. Costs Associated with Cost-Reduction Initiatives and Acquisition Activity

We often incur significant costs in connection with acquiring, restructuring and integrating acquired businesses and in connection with our global cost-reduction initiatives. For example:

for our cost-reduction initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems; and

for our acquisition activity, we typically incur costs that can include transaction costs, integration costs (such as expenditures for consulting and systems integration) and restructuring charges, related to employees, assets and activities that will not continue in the combined company.

On February 1, 2011, we announced a new research and productivity initiative to accelerate our strategies to improve innovation and overall productivity in R&D by prioritizing areas with the greatest scientific and commercial promise, utilizing appropriate risk/return profiles and focusing on areas with the highest potential to deliver value in the near term and over time.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

We incurred the following costs in connection with our cost-reduction initiatives and acquisition activity, such as King (acquired in 2011) and Wyeth (acquired in 2009):

Three Months Ended

(millions of dollars)

April 3,

2011

April 4,

2010

Transaction costs(a)

10

Integration costs(b)

179

208

Restructuring charges(c):

Employee termination costs

667

458

Asset impairments

25

Other

13

25

Restructuring charges and certain acquisition-related costs

894

706

Additional depreciation asset restructuring (d)

Cost of sales

172

13

Selling, informational and administrative expenses

60

Research and development expenses

64

20

Total additional depreciation asset restructuring

243

93

Implementation costs(e)

Research and development expenses

10

Total implementation costs

10

Total costs associated with cost-reduction initiatives and acquisition activity

1,147

799

(a)

Transaction costs represent external costs directly related to business combinations and primarily include expenditures for banking, legal, accounting and other similar services.

(b)

Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and systems integration.

(c)

From the beginning of our cost-reduction and transformation initiatives in 2005 through April 3, 2011, Employee termination costs represent the expected reduction of the workforce by approximately 53,500 employees, mainly in manufacturing and sales and research of which approximately 37,900 employees have been terminated as of April 3, 2011. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Asset impairments primarily include charges to write down property, plant and equipment to fair value. Other primarily includes costs to exit certain assets and activities. These restructuring charges in 2011 are associated with the following: Primary Care operating segment ($46 million), Specialty Care and Oncology operating segment ($35 million), Established Products and Emerging Markets operating segment ($3 million), Animal Health and Consumer Healthcare operating segment ($10 million), Nutrition operating segment ($2 million), Worldwide Research and Development ($422 million) and Corporate ($187 million).

(d)

Additional depreciation asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions related to acquisitions.

(e)

Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction initiatives.

The components of restructuring charges associated with all of our cost-reduction initiatives and acquisition activity follow:

Costs Incurred

Activity

Accrual

(millions of dollars)

2005-2011

Through

April 3,

2011(a)

As of

April 3,

2011(b)

Employee termination costs

9,478

7,160

2,318

Asset impairments

2,333

2,333

Other

914

822

92

Total restructuring charges

12,725

10,315

2,410

(a)

Includes adjustments for foreign currency translation.

(b)

Included in Other current liabilities ($1.7 billion) and Other noncurrent liabilities ($700 million).

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 6. Other (Income)/Deductions Net

The following table sets forth details related to amounts recorded in Other deductions net:

Three Months Ended

(millions of dollars)

April 3,

2011

April 4,

2010

Interest income(a)

(105

(112

Interest expense(a)

458

522

Net interest expense

353

410

Royalty-related income

(171

(142

Net gain on asset disposals

(12

(45

Certain legal matters, net(b)

501

137

Certain asset impairment charges(c)

157

Other, net

(1

52

Other deductions net

827

412

(a)

Interest income decreased in 2011 due to lower interest rates. Interest expense decreased in 2011 due to lower long- and short-term debt balances and the conversion of some fixed-rate liabilities to floating-rate liabilities.

(b)

In 2011, primarily relates to a charge for hormone-replacement therapy litigation (see Note 14. Legal Proceedings and Contingencies).

(c)

In 2011, relates to an IPR&D compound acquired as part of our acquisition of Wyeth.

Note 7. Taxes on Income

Our effective tax rate for continuing operations was 28.7% for the first quarter of 2011, compared to 36.0% for the first quarter of 2010. The lower tax rate for the first quarter of 2011 is primarily the result of:

the extension of the U.S. research and development credit, which was signed into law on December 17, 2010;

the change in the jurisdictional mix of earnings; and

the tax impact of the charges incurred for certain legal matters (see Note 14. Legal Proceedings and Contingencies).

Note 8. Comprehensive Income/(Loss)

The components of comprehensive income/(loss) follow:

Three Months Ended

(millions of dollars)

April 3,

2011

April 4,

2010

Net income before allocation to noncontrolling interests

2,234

2,035

Other comprehensive income/(loss):

Currency translation adjustment and other

1,541

(2,749

Net unrealized (losses)/gains on derivative financial instruments

(135

134

Net unrealized losses on available-for-sale securities

(24

(15

Benefit plan adjustments

117

Total other comprehensive income/(loss)

1,384

(2,513

Total comprehensive income/(loss) before allocation to noncontrolling interests

3,618

(478

Less: Comprehensive income/(loss) attributable to noncontrolling interests

16

(10

Comprehensive income/(loss) attributable to Pfizer Inc.

3,602

(468

11

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 9. Financial Instruments

A. Selected Financial Assets and Liabilities

Information about certain of our financial assets and liabilities follows:

(millions of dollars)

April 3,

2011

Dec. 31,

2010

Selected financial assets measured at fair value on a recurring basis (a) :

Trading securities

155

173

Available-for-sale debt securities(b)

29,482

32,699

Available-for-sale money market funds

1,396

1,217

Available-for-sale equity securities, excluding money market funds(b)

343

230

Derivative financial instruments in receivable positions(c):

Interest rate swaps

339

603

Foreign currency swaps

268

128

Foreign currency forward-exchange contracts

134

494

Total

32,117

35,544

Other selected financial assets(d):

Held-to-maturity debt securities, carried at amortized cost(b)

848

1,178

Private equity securities, carried at cost or equity method

1,156

1,134

Short-term loans, carried at cost

406

467

Long-term loans, carried at cost

237

299

Total

2,647

3,078

Total selected financial assets (e)